Ibrutinib plus Obinutuzumab as Frontline Therapy for Chronic Lymphocytic Leukemia Is Associated with a Lower Rate of Infusion-Related Reactions and with Sustained Remissions after Ibrutinib Discontinuation: A Single-Arm, Open-Label, Phase 1b/2 Clinical Trial NCT0231576

Table 3

Summary of the results.

	Number of patients (%); Ibrutinib plus obinutuzumab (n = 32)
Primary endpoints
ORR	32 (100)
Secondary endpoints
PFS	Not reached
TFS	Not reached
OS	32 (100)
CR	9 (28.5)
MRDneg	4 (12.5)
PR	20 (62)
SD	0 (0)
PD	3 (9)